ArticleMedical science monitor : international medical journal of experimental and clinical research2025
Survival and Cost Analysis of Surgical Mitral Valve Replacement With Different Prostheses: A Nationwide Cohort Study in Taiwan.
Article in Medical science monitor : international medical journal of experimental and clinical research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND The choice of prosthetic valve for surgical mitral valve replacement (SMVR) remains a clinical challenge, particularly in balancing long-term survival with anticoagulation risk and prosthesis durability. In Taiwan, newer-generation tissue valves were introduced in recent years, providing additional options for patients and clinicians. MATERIAL AND METHODS We conducted a nationwide, retrospective cohort study using Taiwan's National Health Insurance Research Database from 2000 to 2017. Adult patients who underwent SMVR were categorized based on the prosthesis type: mechanical valve (MV), porcine bioprosthetic valve (PV), or newer-generation durable-tissue valve (DV). Propensity-score matching (PSM) was applied to minimize baseline differences. Outcomes analyzed included all-cause mortality, index hospitalization cost, length of hospital stay, and re-operation rates within 3 years. RESULTS Among 10 406 patients (5301 MV, 4300 PV, 805 DV), the DV group was older than in the MV group but younger and healthier than in the PV group. After PSM, DV was associated with significantly lower all-cause mortality compared to PV (HR: 0.61; 95% CI: 0.50-0.74; P<0.001) and MV (HR: 0.72; 95% CI: 0.60-0.88; P=0.002). Hospitalization costs and length of stay were highest for PV, moderate for DV, and lowest for MV. Within 3 years, DV showed the lowest re-operation rate (0.75%) compared to MV (1.96%; OR: 2.66, 95% CI: 1.17-6.09) and PV (3.21%; OR: 4.42, 95% CI: 1.94-10.03). CONCLUSIONS In this retrospective cohort, newer durable-tissue valves were associated with favorable early survival, lower short-term re-operation rates, and moderate hospitalization costs compared to older prostheses. However, the limited follow-up, potential confounding, heterogeneity of valve models, and era-related improvements in care preclude definitive conclusions about long-term durability or superiority. These real-world findings highlight the need for individualized prosthesis selection and longer-term prospective studies to confirm these observations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.